A conference co-presented by the IBA Healthcare and Life Sciences Law Committee, the IBA Intellectual Property and Entertainment Law Committee and the IBA Technology Law Committee
Conference Co-Chairs
Özge Atilgan Karakulak Gün + Partners, Istanbul; Member, IBA Intellectual Property and Entertainment Law Committee Advisory Board
Yuval Horn Gornitzky, Tel Aviv
Alejandro Luna Olivares, Mexico City
Cécile Théard-Jallu De Gaulle Fleurance, Paris; Member, IBA Healthcare and Life Sciences Law Committee Advisory Board
Host Committee Co-Chairs
Francisco Brito e Abreu Uría Menéndez, Lisbon
Manuel Duraes Rocha Abreu Advogados, Lisbon; Chair, Food and Supplements Subcommittee, IBA Healthcare and Life Sciences Law Committee
Subjects include:
- Clinical trials: current trends and perspectives at a global level
- Data exclusivity/Bolar – the EU Pharma Package and other jurisdictions
- Antitrust and intellectual property – divisionals, patent settlements, unlawful PTEs and PTAs
- Preventive health and longevity: legal perspectives shaping the future of healthcare
- Cross-border intellectual property litigation
- Integration of pharma and MedTech with hospitals, clinics and pharmacies
- Liability and accountability in open science research
- Combination products (drug-device) regulation: emerging legal complexities
- Preparing for the entry into force of the WIPO GRATK Treaty
- Artificial intelligence and biotechnology: rethinking patent standards
- AI and data rights in life sciences and HealthTech deals (training data, model outputs and infringement risk)
- Collaboration and licensing structures as financing tools
- Life sciences M&A in uncertain markets – earnouts, contingent value rights, contingent milestones and intellectual property-driven valuation mechanics
- Late-stage private financings and IPO alternatives (crossovers, structured preferred, PIPEs, ATMs, registered directs)
- Cross-border investment constraints affecting financings and exits (CFIUS risk, sensitive health/genomic data and closing conditions)